CRDL - Cardiol Therapeutics

-

$undefined

N/A

(N/A)

Cardiol Therapeutics NasdaqCM:CRDL Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Location: 2265 Upper Middle Road East, Oakville, ON, L6H 0G5, Canada | Website: https://www.cardiolrx.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

80.17M

Cash

23.29M

Avg Qtr Burn

-6.323M

Short % of Float

2.34%

Insider Ownership

4.35%

Institutional Own.

10.23%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.